knowledge -WSS

knowledge

author：leisure time 2025-09-29 01:45:34 - browse：1372

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Sanofi seeks simpler, safer CRISPR sickle cell cure

focus

WSS

Why health records don't always know when patients are dead

In Spain, a hospital brews its own CAR

SEC charges former device maker CEO with $41 million fraud

HCA sued by state AG for quality issues at Mission Health

Group opposing PBM reform sets lobbying record

Sanofi seeks simpler, safer CRISPR sickle cell cure

hotspot

knowledge

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

At Orexo, a ‘turning point’ for everything but digital health

The cancer drug shortage isn’t new — and neither are the solutions

FDA approves RSV monoclonal antibody for infants, toddlers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

DIEP, the 'gold standard' of breast reconstruction, is under threat

Albert Bourla of Pfizer: worst biopharma CEO of 2023

State Dept. review finds Biden bears some blame for Afghanistan failures

Sanofi seeks simpler, safer CRISPR sickle cell cure

entertainment

HCA sued by state AG for quality issues at Mission Health

Group opposing PBM reform sets lobbying record

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Startup Neumora takes a novel depression drug to Phase 3

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Medicare to cover more brain scans for Alzheimer’s patients

explore

leisure time

focus

hotspot